(el-TROM-boh-pag OH-luh-meen)
This page contains brief information about eltrombopag olamine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Eltrombopag olamine is approved to treat:
- Thrombocytopenia (low platelet levels). It is used in adults and in children aged 1 year or older with chronic immune thrombocytopenia (ITP). ITP is a condition in which platelets are destroyed by the immune system. Eltrombopag olamine is used in certain patients with ITP who have not gotten better with other treatment.
Eltrombopag olamine is also being studied in the treatment of other conditions and types of cancer.
More About Eltrombopag Olamine
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Eltrombopag Olamine – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Eltrombopag Olamine – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
